Halted Trials Raise New Safety Questions About ‘Rushed’ COVID-19 Vaccines

Oct 17, 2020

In the interest of “transparency”, Pfizer CEO Dr. Albert Bourlas released a statement on Friday outlining the timeline for when its experimental COVID-19 vaccine might be ready for approval for regular, non-emergency use. Much to Trump’s chagrin, CEO Dr. Albert Bourla said the earlier the company expects to apply for an emergency-use approval from the FDA would be the third week of November, after the election has come and gone.

The news capped off what was a busy week for vaccine news, which started Monday night with reports that Phase 3 trials for Johnson & Johnson’s COVID-19 vaccine have been paused after a participant came down with an “unspecified” illness.

While JNJ executives insisted their vaccine candidate likely wasn’t the cause, they brought in investigators and are now working to get the trial going again as quickly as possible. If what happened with the AstraZeneca-Oxford vaccine is any guide, it could be weeks before US regulators sign off on allowing the trial to resume. AstraZeneca-Oxford trial in the US has been paused for more than a month.

Back in September, AstraZeneca briefly halted global studies after UK regulators investigated a pair of patients who came down with symptoms of a rare illness which scientists worried might be connected with the vaccine. Trials in the UK and elsewhere restarted days later, but in the US, regulators have refused to allow the trials to resume.

Already, the time lost by JNJ and AstraZeneca-Oxford has pushed them out of the lead in the race to apply for an emergency use authorization from the FDA. Vaccine candidates being developed by Moderna and Pfizer-BioNTech have taken the lead.

But as Bloomberg pointed out in a piece published Saturday morning, both the AZ and JNJ vaccines relied on the same technique: the so-called adenovirus vector which was also used by the Gameleya Institute’s vaccine (aka Sputnik 5) and at least one of the leading Chinese vaccines.

Still, if these investigations determine a link between the illnesses and the vaccines, this could bolster public skepticism, something that surveys have shown is already alarmingly high.

And this year, with Covid-19 vaccines entering strongly into the politics of the hour, transparency and trust are key to fighting a virus that’s hit more than 39 million people globally and hamstrung economies. If concerns about side effects in experimental vaccines in trials using adenoviruses are validated, it could boost skepticism in the general public and raise questions for other drugmakers.

It would also amount to a considerable setback to adenovirus vector vaccines.

As Bloomberg explains, the adenovirus vaccine vector is nothing new to medicine. They are well studied and versatile, according to Bloomberg. Humans have been shown to easily tolerate them, which is what initially attracted scientists to experiment with this method for COVID-19. A J&J vaccine based partially on the method was recently approved to guard against Ebola.

However, the technique already has a couple of conspicuous blemishes on its safety record. Here’s one example: An AIDS vaccine based on the technique was abandoned after the virus was potentially tied to increased infections among those who received it.

In other experiments, though, there were disappointing results. In 2008, a vaccine using an adenovirus developed by Merck & Co. to prevent HIV was tied to increased infections among some who received it in a trial. Merck abandoned the shot, and several similar programs fell by the wayside.

Article continues at Zerohedge.com

0 Comments

Leave a Reply

News

The Real Pandemic: Mass Munchausen’s Syndrome by Proxy

Authored by Craig Pirrong via The American Institute for Economic Research, It’s more than fair to say that we are experiencing a pandemic, but not the one you hear about ad nauseum. No, the pandemic is not a virus, it is a pandemic outbreak of Munchausen’s...

News

Brazil’s Sao Paulo Pushes For Mandatory COVID Vaccinations

In September, Brazil's wealthiest and most populous state Sao Paulo went into contract with Chinese vaccine developer Sinovac Biotech, with the expectations to receive 46 million doses of CoronaVac. CoronaVac has been in Phase 3 testing in the South American...

News

America’s Front Line Doctors – End The Fear (Full Video)

We exist to counter the massive disinformation campaign regarding the pandemic. We are diverse, exceedingly well-credentialed physicians with extensive front line experience treating COVID-19 and the risky health effects due to the lockdowns. There are many early...

News

Twitter Silences Top Trump COVID Task Force Expert

From Zerohedge.com Social media companies and mainstream media outlets are on a crusade, censoring anyone who challenges the "official" science and narrative behind the COVID-19 virus. It was only last week when Twitter removed New York Post's bombshell stories...

News

Australia Conquers Influenza

As our previous article How We Conquered Influenza After a Century of Failure discussed, nations are suddenly for the first time in history winning the war against Influenza. Today we're covering Australia which has had the most remarkable success of anywhere on...

News

How We Conquered Influenza After a Century of Failure

For centuries humanity has been plagued by influenza. In the United States, according to the CDC an average of 60,000 people are estimated to die each year from influenza. Further its estimated that more than 50 million people experience symptoms and contribute to...

Pin It on Pinterest

Share This
%d bloggers like this: